| Date | Action | Conf | Host / episode | Summary | 7d | 30d | 90d |
|---|---|---|---|---|---|---|---|
| 2026-08-03 | MENTIONED | MEDIUM | Rob Black Show Market Surges As Oil Prices Slide |
Bristol Myers Squibb is the merger target of AstraZeneca and is navigating a patent cliff but has a strong cancer pipeline. [audio] | -1.0% | +3.3% | — |
| 2026-07-27 | WATCH | MEDIUM | Rob Black Show Markets Meander As Oil Falls |
Bristol-Myers Squibb close to breaking out of a three-year base. [audio] | +4.7% | +8.0% | — |
| 2026-07-20 | MENTIONED | LOW | Rob Black Show Afternoon podcast 7-20-26 |
Bristol-Myers Squibb testing bi-specific antibodies and Opdivo immunotherapy. [audio] | +4.0% | +12.4% | — |
| 2026-07-20 | BUY | HIGH | Rob Black Show Oil Prices Fluctuated |
Bristol-Myers Squibb is buying NVIDIA's newest enterprise AI computing system for drug discovery and development. [audio] | +4.0% | +12.4% | — |
| 2026-05-29 | BUY | MEDIUM | Rob Black Show Thinking About A Shopping List |
The host recommends buying Bristol-Myers Squibb, citing a low P/E ratio and the potential for AI-driven growth. [audio] | +0.2% | +0.6% | +18.4% |
| 2026-05-19 | MENTIONED | LOW | Rob Black Show Afternoon podcast 5-19-26 |
Host lists Bristol-Myers Squibb as one of the top 10 stocks in the year 2000. [audio] | -0.5% | -7.4% | +12.1% |